Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sirion Therapeutics Inc.
DescriptionCombination of latanoprost and dorzolamide
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase II
Standard IndicationGlaucoma
Indication DetailsTreat glaucoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today